Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen

[1]  Allen R. Chen,et al.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  M. Ayas,et al.  Second stem cell transplantation in patients with Fanconi anemia using antithymocyte globulin alone for conditioning. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  K. Sullivan,et al.  Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection , 2008, Bone Marrow Transplantation.

[4]  M. Perales,et al.  Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  D. Jacobsohn,et al.  Acute graft-versus-host disease. , 1990, Cancer treatment and research.

[6]  E. Jabbour,et al.  Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation , 2007, Bone Marrow Transplantation.

[7]  Allen R. Chen,et al.  6: Post-transplantation high-dose cyclophosphamide (Cy) is effective single agent GVHD prophylaxis that permits prompt immune reconstitution after myeloablative HLA matched related and unrelated bone marrow transplantation (BMT) , 2007 .

[8]  C. R. Allen,et al.  Post-Transplantation High-Dose Cyclophosphamide (Cy) Is Effective Single Agent GVHD Prophylaxis That Permits Prompt Immune Reconstitution after Myeloablative HLA Matched Related and Unrelated Bone Marrow Transplantation (BMT). , 2006 .

[9]  M. Hallek,et al.  Fludarabine in chronic lymphocytic leukaemia , 2006, Expert opinion on pharmacotherapy.

[10]  A. Felten,et al.  Successful allogeneic bone marrow retransplantation with the same donor after graft rejection: Application of a modified conditioning regimen , 1979, Blut.

[11]  M. Turner,et al.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  M. Aljurf,et al.  Second Allogeneic Bone Marrow Transplantation after Myeloablative Conditioning Analysis of 43 Cases from Single Institution , 2004, Hematology.

[13]  J. Bolaños-Meade,et al.  Acute graft-versus-host disease. , 2004, Clinical advances in hematology & oncology : H&O.

[14]  R. Storb,et al.  Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis). , 1998, Blood.

[15]  C Anasetti,et al.  Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. , 1998, The New England journal of medicine.

[16]  J. Cornish,et al.  Second allogeneic bone marrow transplants from unrelated donors for graft failure following initial unrelated donor bone marrow transplantation , 1998, Bone Marrow Transplantation.

[17]  H. Holland,et al.  Successful engraftment after primary graft failure in aplastic anemia using G-CSF mobilized peripheral stem cell transfusions , 1997, Bone Marrow Transplantation.

[18]  H. Deeg,et al.  Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience. , 1996, Transplantation.

[19]  H. Deeg,et al.  Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. , 1994, Blood.

[20]  J. Radich,et al.  Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Piantadosi,et al.  Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Rimm,et al.  Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. , 1989, Blood.

[23]  K. Sullivan,et al.  Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. , 1989, The New England journal of medicine.

[24]  K. Sullivan,et al.  Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. , 1987, Blood.

[25]  R. Brookmeyer,et al.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.

[26]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[27]  A. Britten,et al.  Successful retransplantation of bone marrow following failure of initial engraftment in a patient with aplastic anemia. , 1976, Jornal de Pediatria.

[28]  Bone marrow transplantation from donors with aplastic anemia. A report from the ACS/NIH bone marrow transplant registry. , 1976, JAMA.

[29]  J. Kersey,et al.  RETRANSPLANTATION OF HUMAN BONE MARROW: Two IMMUNOSUPPRESSIVE DRUG REGIMENS , 1975, Transplantation.